Home Featured Page 113

Featured

Latest

Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on the First Patients, Payers and Practicalities

Out of This World: Why AI Belongs Beside the Therapist

Psychedelic Policy Briefing: June 11, 2026

May 2026 Psychedelic Bill Roundup

Algernon NeuroScience Announces Successful Dosing of 2nd Cohort in Phase 1...

First Avenue Ventures Life Science Fund I Invests in Diamond Therapeutics...

Algernon NeuroScience Announces U.S. SEC Qualification of Regulation A+ Tier II...

Psyence Group Announces Closing of Fourth Tranche of Private Placement and...

Reunion Neuroscience Appoints Dr. Fred Grossman to Board of Directors

Revive Therapeutics Advances MDMA Transdermal Patch Development with Purchase of MDMA...

Mindset Pharma to Participate in the Sequire Cannabis & Psychedelics Conference...

FILAMENT HEALTH REPORTS Q4 AND YEAR END 2022 FINANCIAL RESULTS AND...

Psychedelics Weekly – Investors Form REIT for Psychedelic Therapy, Diplo Runs...

PT402 – Magic, Virtual Reality, and Ketamine & Internal Family Systems

EDITOR PICKS

Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on...

Out of This World: Why AI Belongs Beside the Therapist

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on the First Patients, Payers and Practicalities

Out of This World: Why AI Belongs Beside the Therapist

Shroomski Melt

Psychedelic Policy Briefing: June 11, 2026

May 2026 Psychedelic Bill Roundup

Algernon NeuroScience Announces Successful Dosing of 2nd Cohort in Phase 1...

First Avenue Ventures Life Science Fund I Invests in Diamond Therapeutics...

Algernon NeuroScience Announces U.S. SEC Qualification of Regulation A+ Tier II...

Psyence Group Announces Closing of Fourth Tranche of Private Placement and...

Reunion Neuroscience Appoints Dr. Fred Grossman to Board of Directors

Revive Therapeutics Advances MDMA Transdermal Patch Development with Purchase of MDMA...

Mindset Pharma to Participate in the Sequire Cannabis & Psychedelics Conference...

FILAMENT HEALTH REPORTS Q4 AND YEAR END 2022 FINANCIAL RESULTS AND...

Psychedelics Weekly – Investors Form REIT for Psychedelic Therapy, Diplo Runs...

PT402 – Magic, Virtual Reality, and Ketamine & Internal Family Systems

EDITOR PICKS

Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on...

Out of This World: Why AI Belongs Beside the Therapist

Shroomski Melt

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY